The present work highlights the potential of targeting miR-27a-3p to disrupt A172 cells, which may be the basis for identifying new therapeutic targets and strategies to modulate the survival mechanisms of tumor cells through post-transcriptional regulations and key pathways, like TGF-β signaling. This evidence concerns the gene TGFB1 and neoplasm.